The analysis indicated no significant causal link between the gene expression of NPC1L1 inhibitors and the onset of gout and urate levels, implying that the side effects associated with NPC1L1 inhibitors in patients suffering from gout and urate might be inferior to those arising from HMGCR and PCSK9 inhibitors. The gene discussed is NPC1L1; the disease is gout.